Getting on Target for Alzheimer’s
Biogen revitalizes hope for Alzheimer’s therapy, but their work highlights why we still need greater selectivity
Neil Cashman, James Kupiec | | Opinion
In October 2019, Biogen sent shockwaves through the Alzheimer’s community when it reanimated aducanumab, its previously dismissed therapy candidate for Alzheimer’s disease. Upon analysis of additional data supporting aducanumab’s efficacy in patients with longer term, high-dose exposure, Biogen plans to now submit the drug candidate for FDA approval in early 2020. If approved, aducanumab will be the first disease-modifying therapy for Alzheimer’s, which, as a reminder, is currently the only disease on the “top ten” causes of death without treatment.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.